Source comparison
ARA-290 vs BPC-157: Research Comparison
Primary Mechanism Innate repair receptor (IRR) agonist; JAK2/STAT3 activation; tissue-protective signaling Multi-pathway: VEGF upregulation, angiogenesis, FAK-paxillin modulation, collagen synthesis ARA-290 for receptor-specific studies; BPC-157 for multi-targ
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Innate repair receptor (IRR) agonist; JAK2/STAT3 activation; tissue-protective signaling
- Multi-pathway: VEGF upregulation, angiogenesis, FAK-paxillin modulation, collagen synthesis
- ARA-290 for receptor-specific studies; BPC-157 for multi-target healing
- Clinical Evidence
- Phase 2 RCTs in humans (diabetic neuropathy, sarcoidosis neuropathy); published in Diabetes Care, The Lancet
- Extensive rodent/animal studies; no large-scale human RCTs; mainly Croatian research groups
- ARA-290 has validated human dosing; BPC-157 lacks Phase 2/3 data
- Primary Applications
- Neuroprotection, diabetic neuropathy, inflammatory small fiber neuropathy, tissue protection under oxidative stress
- Musculoskeletal injury (tendon, ligament, muscle), wound healing, gastrointestinal protection, angiogenesis
- Choose based on target tissue: neural vs musculoskeletal
- Administration Route
- Subcutaneous injection; daily dosing required
- Subcutaneous (near injury site), oral, or intraperitoneal; flexible dosing
- BPC-157 offers route flexibility; ARA-290 requires injection consistency
- Typical Dose Range
- 1–4mg/day (human trials); 4mg optimal in published studies
- 10μg/kg in animals; ~200–500μg/day extrapolated to humans (not validated)
- ARA-290 dosing is evidence-based; BPC-157 requires extrapolation
- Half-Life
- 5–8 hours; requires daily dosing to maintain levels
- 2–4 hours; but downstream effects persist 24–48 hours post-dose
- Both require consistent dosing; ARA-290 needs continuous presence
- Stability
- Temperature-sensitive; must refrigerate 2–8°C after reconstitution; degrades rapidly >8°C
- Stable in gastric acid; more temperature-tolerant; easier field storage
- BPC-157 logistically simpler for protocols with storage constraints
- Adverse Events
- Mild injection site reactions (<10%); no serious AEs in trials; does not stimulate erythropoiesis
- Essentially no toxicity in animal studies even at 100× dose; human safety data anecdotal
- Both appear well-tolerated; ARA-290 has formal safety data
- Regulatory Status
- Orphan drug designation (FDA); investigational; not approved for clinical use
- No regulatory status; purely research compound; not approved anywhere
- Neither is clinically approved as of 2026
- Cost Relative
- Higher (complex synthesis; EPO-derived structure)
- Moderate (simpler peptide chain; more vendors)
- Budget accordingly; ARA-290 costs 2–3× per mg